Image courtesy of Abbott

Abbott Launches Molecular Point-of-Care test to Detect Novel Coronavirus in as Little as Five Minutes

Originally posted on Abbott.com

– The Abbott ID NOW™ COVID-19 test brings rapid testing to the front lines

– Test to run on Abbott’s point-of-care ID NOW platform – a portable instrument that can be deployed where testing is needed most

– ID NOW has the largest molecular point-of-care installed base in the U.S. and is available in a wide range of healthcare settings

– Abbott will be making ID NOW COVID-19 tests available next week and expects to ramp up manufacturing to deliver 50,000 tests per day

– This is the company’s second test to receive Emergency Use Authorization by the FDA for COVID-19 detection; combined, Abbott expects to produce about 5 million tests per month

Abbott announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes. The test will run on the company’s ID NOW platform, providing rapid results in a wide range of healthcare settings such as physicians’ offices, urgent care clinics and hospital emergency departments.

The ID NOW platform is small, lightweight (6.6 pounds) and portable (the size of a small toaster), and uses molecular technology, which is valued by clinicians and the scientific community for its high degree of accuracy. ID NOW is already the most widely available molecular point-of-care testing platform in the U.S. today.

“The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus,” said Robert B. Ford, president and chief operating officer, Abbott. “With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots.”

Abbott will be making ID NOW COVID-19 tests available next week to healthcare providers in urgent care settings in the U.S., where the majority of ID NOW instruments are in use today. The company is working with the Administration to deploy tests to areas where they can have the greatest impact.

The arrival of the Abbott ID NOW COVID-19 test comes a week after the company launched its Abbott m2000™ RealTime SARS-CoV-2 EUA test, which runs on the m2000 RealTime System located in hospital and reference labs around the world. Between the two platforms, Abbott expects to produce about 5 million tests per month.

About the ID NOW Molecular Platform
As the world leader in point-of-care diagnostics, Abbott is adding its expertise and scale to help fight the COVID-19 global pandemic. First introduced in 2014, ID NOW is the leading molecular point-of-care platform for Influenza A & B, Strep A and RSV testing in the U.S.

ID NOW is a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. Its unique isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing clinicians to make evidence-based clinical decisions during a patient visit.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

 

Latest News

Video: How Companies Are Ensuring Equity for People With Disabilities

The National Organization on Disability held its annual forum in Washington, D.C. last week, bringing together community leaders, advocates, government officials and corporate leaders and influencers to focus on the advancement of people with disabilities in the workplace. DiversityInc also met up with leaders from Capital One Financial (No. 22…

Validated Allies wallpaper

DiversityInc Announces 2022 Validated Allies

Allyship is a journey rather than a destination. The work of an ally never really ends and allies understand they are not necessarily always working toward a goal, but rather, serving a greater purpose. Each year, as part of our Women of Color and Their Allies event, DiversityInc recognizes a…

CDO Series: Sysco’s Adrienne Trimble

Following the murder of George Floyd, the role of Chief Diversity Officers has become more important as companies started to be more intentional with their diversity, equity and inclusion efforts, which has made the last few years tumultuous for many CDOs. In the latest installment of a series of articles…

NOD Forum: Honoring the Disability Rights Movement

The road to disability rights has been a long one. One that started long before the Americans with Disabilities Act (ADA) of 1990 was passed. In celebration of 40 years of the National Organization on Disability, disability leaders, supporters and activists gathered in Washington, D.C last week to discuss the…

5 Biggest News Stories of the Week: September 29

As the saying goes, the news never stops — but there’s a lot of it out there, and all of it doesn’t always pertain to our readers. In this weekly news roundup, we’ll cover the top news stories that matter most to our diversity focused audience. 1. Research Outlines Lack…

Humana Ranks Highly in the Hispanic Association on Corporate Responsibility Inclusion Index

Originally published at press.humana.com. Humana ranked No. 9 on The DiversityInc Top 50 Companies for Diversity list in 2022.   Humana Inc. celebrates the high rankings it recently received in the 2022 Hispanic Association on Corporate Responsibility (HACR) Corporate Inclusion Index (CII), a research initiative that measures Hispanic inclusion in the…